Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

NCT04439240 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

NIH

Sponsor class

Conditions

Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Plasma Cell Myeloma

Interventions

DRUG: FGFR Inhibitor AZD4547

Sponsor

National Cancer Institute (NCI)